Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, announced that a New Drug Application (NDA) has been submitted for EMBEDA™, a pharmacological abuse-deterrent, extended-release morphine product candidate. “Today’s announcement is an important one for all stakeholders in Alpharma,” commented Dean Mitchell, President and Chief Executive Officer.